Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials
Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese et autres
0 citationsnpj Parkinson s Disease
Agnès Poirier
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
35Publications signalées
1842Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Drug Transport and Resistance MechanismsPharmacogenetics and Drug MetabolismNeurogenetic and Muscular Disorders ResearchPharmacological Effects and Toxicity StudiesRNA modifications and cancer
Publications récentes
Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab
Kirsten I. Taylor, Florian Lipsmeier, Marzia A. Scelsi, Ekaterina Volkova-Volkmar et autres
14 citationsnpj Digital Medicine
RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models
Uwe Grether, Richard Foxton, Sabine Gruener, Claudia Korn et autres
10 citationsFrontiers in Pharmacology
Addressing Today’s Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam
Stephen Fowler, Andreas Brink, Yumi Cleary, Andreas Günther et autres
24 citationsDrug Metabolism and Disposition
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs
Agnès Poirier, Marla Weetall, Katja Heinig, Franz Bucheli et autres
173 citationsPharmacology Research & Perspectives
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier
Stefan Sturm, Andreas Guenther, Birgit Jaber, Paul Jordan et autres
104 citationsBritish Journal of Clinical Pharmacology
Estimation of the non-genotoxic effect level in vivo in bone marrow micronucleus tests for a rare disease drug candidate
Lutz Mueller, Andreas Zeller, Melanie Guérard, Agnès Poirier
0 citationsToxicology Letters
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2 ) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni, Martin Ebeling, John D. Baird, Stefanie Bendels et autres
537 citationsJournal of Medicinal Chemistry
Relationship Between Central and Peripheral SMN Protein Increase Upon Treatment with RO7034067 (RG7916) (S46.007)
Agnès Poirier, Marla Weetall, Hasane Ratni, Katja Heinig et autres
1 citationNeurology
Oral SMN2 splicing modifiers in spinal muscular atrophy: Proof-of-mechanism and ongoing clinical studies
Anne Marquet, Stefan Sturm, Heidemarie Kletzl, Andreas Günther et autres
1 citationEuropean Journal of Paediatric Neurology
Xylella fastidiosa: the status of the infection and control measures in France
Bruno Legendre, Nicolás Denancé, Valérie Olivier, Dimitri Molusson et autres
1 citationHAL (Le Centre pour la Communication Scientifique Directe)
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy
Hasane Ratni, Gary M. Karp, Marla Weetall, Nikolai A. Naryshkin et autres
117 citationsJournal of Medicinal Chemistry
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.